Dermata Therapeutics Changes Independent Auditor, Appointing Former Firm CBIZ CPAs
DRMA sits 20% above its 52-week low of $1.58 on light trading volume (0.2× avg).
Summary
Dermata Therapeutics, Inc. announced the dismissal of Baker Tilly US, LLP as its independent auditor and the appointment of CBIZ CPAs P.C., which previously served the company, with no reported disagreements.
Key Events · Corporate Governance and Compliance · DRMA
-
Auditor Dismissal
Dermata Therapeutics dismissed Baker Tilly US, LLP as its independent registered public accounting firm, effective January 31, 2026.
-
No Disagreements Reported
The company stated there were no disagreements on accounting principles or reportable events with Baker Tilly, though prior audit reports included a going concern explanatory paragraph.
-
New Auditor Appointment
CBIZ CPAs P.C. was appointed as the new independent auditor, effective February 2, 2026.
-
Return to Former Auditor
CBIZ CPAs previously served as the company's auditor from 2016 to 2023.
Analysis · DRMA · Life Sciences
This 8-K filing details a change in Dermata Therapeutics' independent registered public accounting firm. While the dismissal of an auditor can often be a red flag, the company explicitly stated that there were no disagreements on accounting principles or reportable events with the outgoing firm, Baker Tilly. It is notable that Baker Tilly's previous audit reports included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, a pre-existing concern for investors. The appointment of CBIZ CPAs P.C., a firm that previously audited the company, could suggest a move towards a familiar and established relationship. For a micro-cap company like Dermata Therapeutics, maintaining stable and credible financial oversight is crucial, especially given its ongoing financial challenges. Investors will monitor future financial statements for any new disclosures or changes in audit opinions.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRMA was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.58 to $23.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.